Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

Published:2019-04 Issue:4 Volume:7 Page:325-335
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

McNamara John J,McColley Susanna A,Marigowda Gautham,Liu Fang,Tian Simon,Owen Caroline A,Stiles David,Li Chonghua,Waltz David,Wang Linda T,Sawicki Gregory S

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference32 articles.

1. Cystic fibrosis in young children: a review of disease manifestation, progression, and response to early treatment;VanDevanter;J Cyst Fibros,2016

2. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening;Hoo;Thorax,2012

3. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening;Stick;J Pediatr,2009

4. Early lung disease in cystic fibrosis;Grasemann;Lancet Respir Med,2013

5. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus;Döring;J Cyst Fibros,2004

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Care and Outcomes for Children with Cystic Fibrosis;Clinics in Chest Medicine;2024-09

2. Immune Response and Exhaled Breath Profile Changes after Initiation of CFTR Modulator Therapy in Children with CF;International Journal of Translational Medicine;2024-08-27

3. Impact of lumacaftor/ivacaftor on nutrition and growth in modulator-naïve children over 24 weeks;Journal of Cystic Fibrosis;2024-07

4. Cystic fibrosis patient characteristics and healthcare resource utilization in Finland using linked registries;Heliyon;2024-07

5. Recommended Tool Compounds for Modifying the Cystic Fibrosis Transmembrane Conductance Regulator Channel Variants;ACS Pharmacology & Translational Science;2024-03-14